Manmeet S. Ahluwalia, MD, of the Taussig Center Institute, Cleveland Clinic, discusses phase II findings on the efficacy and immunogenicity of SurVaxM, a novel cancer vaccine targeting the tumor-specific antigen survivin in newly diagnosed glioblastoma (Abstract 2016).
Åsmund A. Fretland, MD, of Oslo University Hospital, discusses clinical trial findings on survival outcomes after laparoscopic vs open resection for colorectal liver metastases. The study he conducted with his team showed that the laparoscopic procedure did not jeopardize long-term survival (Abstract LBA3516).
Sara A. Hurvitz, MD, of the UCLA Jonsson Comprehensive Cancer Center, discusses the first study of ribociclib plus endocrine therapy vs endocrine therapy alone to demonstrate significantly longer overall survival in peri- and premenopausal women with advanced breast cancer (Abstract LBA1008).
Michael J. Morris, MD, of Memorial Sloan Kettering Cancer Center, discusses the phase III findings from the Alliance A031201 trial, which showed that adding abiraterone acetate to enzalutamide did not improve survival in men with metastatic castration-resistant prostate cancer (Abstract 5008).
Edward B. Garon, MD, of the David Geffen School of Medicine at the University of California, Los Angeles, discusses long-term survival data on patients with advanced non–small cell lung cancer treated with pembrolizumab and those with PD-L1 expressed in at least half of their tumor cells (Abstract LBA9015).
Amy J. Davidoff, PhD, of Yale University School of Public Health, discusses study findings on how expanding access to Medicaid through the Affordable Care Act (ACA) reduced racial disparities among patients with advanced cancer. Before the ACA was implemented in 2014, black patients with cancer were less likely than white patients to receive timely treatment, but in states that did not adopt Medicaid expansion, racial disparities persist (Abstract LBA1).
